BCAL Diagnostics (ASX:BDX) Common Stock: A$33.95 Mil (As of Dec. 2025)


What is BCAL Diagnostics Common Stock?

BCAL Diagnostics ASX:BDX +4.17% Common Stock is A$33.95 Mil as of Dec. 2025. The stock has 3 warning signs investors should review.

BCAL Diagnostics's quarterly common stock declined from Dec. 2024 (A$33.84 Mil) to Jun. 2025 (A$33.84 Mil) but then increased from Jun. 2025 (A$33.84 Mil) to Dec. 2025 (A$33.95 Mil).

BCAL Diagnostics's annual common stock increased from Jun. 2023 (A$19.28 Mil) to Jun. 2024 (A$28.90 Mil) and increased from Jun. 2024 (A$28.90 Mil) to Jun. 2025 (A$33.84 Mil).

BCAL Diagnostics Common Stock Historical Data

* Premium members only.

The historical data trend for BCAL Diagnostics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BCAL Diagnostics Common Stock Chart

BCAL Diagnostics Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Common Stock
18.87 19.28 28.90 33.84

BCAL Diagnostics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.80 28.90 33.84 33.84 33.95

BCAL Diagnostics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of A$33.95 Mil mean?
BCAL Diagnostics (ASX:BDX) has a Common Stock of A$33.95 Mil as of Dec. 2025. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on BCAL Diagnostics and its competitors.
Is BCAL Diagnostics' Common Stock too high?
BCAL Diagnostics' current Common Stock is A$33.95 Mil.
How does BCAL Diagnostics' Common Stock compare to TMO and DHR?
BCAL Diagnostics' Common Stock of A$33.95 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Medical Diagnostics & Research company?
A good Common Stock depends on the Medical Diagnostics & Research industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on BCAL Diagnostics and its competitors. BCAL Diagnostics's current Common Stock is A$33.95 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BCAL Diagnostics stock overvalued right now?
BCAL Diagnostics (ASX:BDX) has a current Common Stock of A$33.95 Mil. The current Common Stock is A$33.95 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For BCAL Diagnostics (ASX:BDX), the current Common Stock is A$33.95 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BCAL Diagnostics Business Description

Address 50 Clarence Street, Suite 506, Level 5, Sydney, NSW, AUS, 2000
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, cost-effective, accurate, and available to all women regardless of age, race, and geographic location.